Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
1994-08-17
2002-08-13
Bui, Phuong T. (Department: 1638)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S325000, C424S093700, C424S093710, C436S531000, C436S824000
Reexamination Certificate
active
06432653
ABSTRACT:
TECHNICAL FIELD
The subject field concerns cellular separations employing devices having specificity for cell surface proteins. Particularly, the cellular source will be blood, spinal fluid, bone marrow, tumor homogenates, lymphoid tissue and the like.
BACKGROUND
There are numerous situations where it is of interest to isolate a specific class of cells or to remove a particular set of cells from a mixture of cells. Techniques which have been employed include fluorescence cell sorting, magnetic immunobeads, complement-mediated lysis, affinity chromatography, centrifugal elutriation and polystyrene panning of cells. Cells having substantial density differences, such as that between platelets and red cells can be grossly fractionated by gradient centrifugation methodologies. However, mammalian cells with equivalent densities, such as tumor cells, lymphocyte subsets, granulocytes, or stem cells, require some form of separation using molecular recognition of surface markers which correlate with their phenotype. Similarly, such molecular mechanisms are required to separate viruses and bacteria from one another in complex mixtures. Each of the aforementioned methods have serious drawbacks for many applications, where there is interest in isolation or removal of particular subsets of cells.
Disadvantages of fluorescence activated cell sorting for recovery of viable sorted cells are the slowness of the procedure, the fact that the isolated cells are coated with antibody, and the limited amounts of cells which can be obtained by the procedure.
With immunobeads, it is difficult to recover the cells from the beads after separation; the cells are frequently coated with antibody and magnetic beads, and distinct separations are only difficultly achieved. Complement mediated lysis is problematic for two reasons: first, depletion of target cells is incomplete, and second, non-target cells can be adversely affected by exposure to complement and the toxic by-products of target cell lysis. Affinity chromatography of cells using, for example, Sephadex G-10 coupled to antibody, suffers from poor recovery and inefficient depletion of target cells. Centrifugal elutriation is not capable of separating different phenotypic subpopulations of cells of like size.
The last methodology, panning developed by Wysocki and Sato, PNAS, 75:2844, (1978), utilizing passively adsorbed antibody on polystyrene, is particularly inadequate,. only low recoveries can be achieved, and the process suffers from lack of specificity and contamination of the separated cells with antibody.
As the immune defense system becomes elucidated, it is increasingly evident that subsets of cells can have relatively narrow ranges of activities. Thus, subsets can be specialized for response to a particular disease, such as neoplasia, infection, viral or cellular, etc., response to transplants, and the like. It is therefore of great interest to be able to identify and purify these subsets of cells, not only to understand their action, but also to use these cells for prophylactic and therapeutic purposes. In order to achieve the desired results, it is necessary that substantially pure populations of the desired subset or subsets of cells can be obtained. Furthermore, the cells should be: (1) free of antibodies on their surface, (2) viable, (3) capable of fulfilling their normal function and (4) responsive to activation by biologicals in the same manner as normal cells in their normal environment.
SUMMARY OF THE INVENTION
Methods, compositions and devices are provided for the selective capture and release of biological particles capable of replication, particularly virus particles and cells. A medium containing the particles is contacted with a solid support having a high density of specific receptor sites, whereby particles having the complementary ligand become bound to the surface. The biological particles may be released from the receptors by either biological activation resulting in ligand shedding and release or physical means such as pipetting, mechanical vibration or ultrasonic sound, as appropriate. The cells can be numerically expanded, subjected to biologicals or other factors for differentiation and/or activation, or the like, and may be used for research, diagnostic, prophylactic and/or therapeutic purposes.
REFERENCES:
patent: 1676579 (1928-07-01), Sperti et al.
patent: 3016336 (1962-01-01), Scott et al.
patent: 3645849 (1972-02-01), Gray
patent: 3956219 (1976-05-01), Smithwick
patent: 3974110 (1976-08-01), Patchornik et al.
patent: 4250139 (1981-02-01), Luck et al.
patent: 4438198 (1984-03-01), Schmer
patent: 4460445 (1984-07-01), Rekers
patent: 4464165 (1984-08-01), Pollard, Jr.
patent: 4497796 (1985-02-01), Salser et al.
patent: 4614513 (1986-09-01), Bensinger
patent: 4620908 (1986-11-01), Van Duzer
patent: 4654299 (1987-03-01), Lentfer
patent: 4690915 (1987-09-01), Rosenberg
patent: 4699877 (1987-10-01), Cline et al.
patent: 4714680 (1987-12-01), Civin
patent: 4727027 (1988-02-01), Wiesehahn et al.
patent: 4736019 (1988-04-01), Bellattar et al.
patent: 4933410 (1990-06-01), Okrongly
patent: 5081029 (1992-01-01), Zarling et al.
patent: 5081030 (1992-01-01), Civin
patent: 5126132 (1992-06-01), Rosenberg
patent: 5215926 (1993-06-01), Btchells, III et al.
patent: 5241012 (1993-08-01), Clark
patent: 0140489 (1985-05-01), None
patent: 0294059 (1988-12-01), None
patent: 0 294 059 (1988-12-01), None
patent: 2-150274 (1990-06-01), None
patent: WO 87/104628 (1987-08-01), None
patent: WO 88/01642 (1988-03-01), None
patent: WO 88/04692 (1988-06-01), None
Basch et al., “Cell Separation Using Positive Immunoselective Techniques,”Journal of Immunological Methods, vol. 56, pp. 269-280 (1983).*
Leivestad et al., “Positive selection of activated T cells of the T8 (CD8) sub-type by immunomagnetic separation,”Tissue Antigens, vol. 28, pp. 46-52 (1986).*
Rutishauser, Urs, “Specific Fractionation and Manipulation of Lymphocytes with Derivatized Nylon Fibers,”Immunochemistry, vol. 12, pp. 603-606 (1975).*
Bidey, Stephen, “Immunobilized Mammalian Cells in Hormone Detection and Quantitation,”in Immoblized Cells and Enzymes: A Practical Approach, J. Woodward, Ed. IRL Press, Washington, D.C., pp. 150-151, (1985).*
Tijssen, P., “The Immobilization of Immunoreactants on Solid Phases,” inLaboratory Techniques in Biochemistry and Molecular Biology, vol. 15, Practice and Theory of Enzyme Immunoassays, Burdon et al., Eds., Elsevier, New York, pp. 305-309, (1985).*
Kessler et al., “Large-Scale Purification and Characterization of CD34-Positive Hematopoietic Progenitor Cells,”Blood, Supplement 1, p. 321a, (1987).*
Freshney (1987) “Culture of Animal Cells”, Alan R. Liss, New York, p. 129.*
Wysocki, et al. “Panning” for lymphocytes : A method for cell Selection PNAS (USA) vol. 75 No. 6 pp. 2844-2848 1978.*
Slingluff, Jr.,et al Human cytotoxic T cells specific for autologous melanoma cells : successful generation from lymph node cells . . . J. National Cancer Institute vol. 80 pp. 1016-1026 1988.*
Walker, et. al. CD8+ lymphocytes can control acute HIV infection of CD4+ T cells (meeting abstract) presented at 5thInternational Conference on AIDS Montreal, International Development Research Centre, Health & Welfare Canada , World Health Organization p. 520.*
Zanders, etal Early biochemical events in T lymphocytes activated by anti T3 pp. 209-217 in Human T cell Clones Feldmann, et.al (eds.) Humana Press, Clifton New Jersey 1985.*
Hunt , inHandbook of Experimental Immunology 2 : Cellular Immunology; Weir, et al. (editors) , 4thEdition , Blackwell Scientific Publications ; Oxford , pp. 55.7-55.8; 1986.*
Funderud, et al., inLymphocytes A Practical Approach; Klaus, Ed. IRL Press , Oxford, Washington D.C. ; pp. 62-64; 1987.*
Slineluff,Jr. et.al “Human cytotoxic T cells specific for autologous melanoma cells: successful generation from lymph node cells . . . ” J. Natl. Cancer Inst. , vol. 80, No. 13, pp. 1016-1026 Sep. 1988.*
Wysocki, et.al. “Panning for Lymphocytes: A method for cell selection” Proc. Natl. Acad. Sciences USA, vol. 75, No. 6, pp 2844-2848, 19
Aventis Pharmaceuticals Inc.
Bui Phuong T.
LandOfFree
Device and process for cell capture and recovery does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Device and process for cell capture and recovery, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Device and process for cell capture and recovery will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2908011